Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||CD274 positive|
|Indication/Tumor Type||head and neck squamous cell carcinoma|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|CD274 positive||head and neck squamous cell carcinoma||sensitive||Pembrolizumab||Guideline||Actionable||Keytruda (pembrolizumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with CD274 (PD-L1)-positive (CPS >/=1) recurrent or metastatic head and neck squamous cell carcinoma (PMID: 34844180; ESMO.org).||detail... 34844180|
|CD274 positive||head and neck squamous cell carcinoma||sensitive||Pembrolizumab||FDA approved - On Companion Diagnostic||Actionable||In a Phase III trial (KEYNOTE-048) that supported FDA approval, Keytruda (pembrolizumab) monotherapy significantly improved overall survival compared to Erbitux (cetuximab) plus chemotherapy (12.3 vs 10.3 months, HR=0.78, p=0.0086) in patients with CD274 (PD-L1)-positive (CPS >=1) metastatic or unresectable recurrent head and neck squamous cell carcinoma (PMID: 31679945; NCT02358031).||detail... 31679945 detail...|
|CD274 positive||head and neck squamous cell carcinoma||sensitive||Pembrolizumab||Guideline||Actionable||Keytruda (pembrolizumab) is included in guidelines as first-line therapy for patients with CD274 (PD-L1)-positive recurrent, unresectable, or metastatic non-nasopharyngeal head and neck squamous cell carcinoma (NCCN.org).||detail...|
|PubMed Id||Reference Title||Details|
|ESMO Clinical Practice Guidelines||Full reference...|
|Keytruda (pembrolizumab) FDA Drug Label||Full reference...|
|(31679945)||Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.||Full reference...|
|(34844180)||Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck.||Full reference...|